{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:12:01Z","timestamp":1791389521138,"version":"4.3.3"},"reference-count":6,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jaad.2018.02.031","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T23:56:22Z","timestamp":1525996582000},"page":"1207-1209.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis"],"prefix":"10.1016","volume":"78","author":[{"given":"Elana","family":"Putterman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Castelo-Soccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jaad.2018.02.031_bib1","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s12325-017-0542-7","article-title":"The changing landscape of alopecia areata: the therapeutic paradigm","volume":"34","author":"Renert-Yuval","year":"2017","journal-title":"Adv Ther"},{"key":"10.1016\/j.jaad.2018.02.031_bib2","unstructured":"US National Institutes of Health ClinicalTrials.gov website. Tofacitinib for the treatment of alopecia areata and variants. Available at: http:\/\/clinicaltrials.gov\/show\/NCT02197455. Accessed September 20, 2017."},{"issue":"1","key":"10.1016\/j.jaad.2018.02.031_bib3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.02.031_bib4","unstructured":"US National Institutes of Health ClinicalTrials.gov website. Topical tofacitinib for the treatment of alopecia areata and\u00a0its\u00a0variants. Available at: http:\/\/clinicaltrials.gov\/show\/NCT02812342. Accessed September 20, 2017."},{"issue":"2","key":"10.1016\/j.jaad.2018.02.031_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaad.2017.10.043","article-title":"Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients","volume":"78","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.02.031_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archderm.1984.01650400039010","article-title":"Alopecia areata treatment with topical minoxidil","volume":"120","author":"Weiss","year":"1984","journal-title":"Arch Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218303165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218303165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:45:34Z","timestamp":1759272334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218303165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0190962218303165"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.02.031","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}